EA200300406A1 - Фармацевтическая композиция дронедарона для парентерального введения - Google Patents

Фармацевтическая композиция дронедарона для парентерального введения

Info

Publication number
EA200300406A1
EA200300406A1 EA200300406A EA200300406A EA200300406A1 EA 200300406 A1 EA200300406 A1 EA 200300406A1 EA 200300406 A EA200300406 A EA 200300406A EA 200300406 A EA200300406 A EA 200300406A EA 200300406 A1 EA200300406 A1 EA 200300406A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
drunedaron
parenteral introduction
physiologically acceptable
composition
Prior art date
Application number
EA200300406A
Other languages
English (en)
Other versions
EA005314B1 (ru
Inventor
Фредерик Буррьягэ-Сев
Тьерри Брёль
Original Assignee
Санофи-Синтелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Синтелябо filed Critical Санофи-Синтелябо
Publication of EA200300406A1 publication Critical patent/EA200300406A1/ru
Publication of EA005314B1 publication Critical patent/EA005314B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Данное изобретение относится к фармацевтической композиции для парентерального введения, отличающейся тем, что она содержит: дронедарон или одну из его фармацевтически приемлемых солей в качестве активного начала; физиологически приемлемый буферный раствор, способный поддерживать pH композиции от 3 до 5; физиологически приемлемое водорастворимое производное β-циклодекстрина.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300406A 2000-12-11 2001-12-10 Фармацевтическая композиция дронедарона для парентерального введения EA005314B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0016071A FR2817750B1 (fr) 2000-12-11 2000-12-11 Composition pharmaceutique de dronedarone pour administration parenterale
PCT/FR2001/003903 WO2002047660A1 (fr) 2000-12-11 2001-12-10 Composition pharmaceutique de dronedarone pour administration parenterale

Publications (2)

Publication Number Publication Date
EA200300406A1 true EA200300406A1 (ru) 2003-10-30
EA005314B1 EA005314B1 (ru) 2004-12-30

Family

ID=8857483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300406A EA005314B1 (ru) 2000-12-11 2001-12-10 Фармацевтическая композиция дронедарона для парентерального введения

Country Status (31)

Country Link
US (1) US6939865B2 (ru)
EP (1) EP1343473B1 (ru)
JP (1) JP4399161B2 (ru)
KR (1) KR100849758B1 (ru)
CN (1) CN1235566C (ru)
AR (1) AR031649A1 (ru)
AT (1) ATE348599T1 (ru)
AU (2) AU1722902A (ru)
BG (1) BG66187B1 (ru)
BR (1) BR0116060B1 (ru)
CA (1) CA2427375C (ru)
CZ (1) CZ297788B6 (ru)
DE (1) DE60125411T2 (ru)
EA (1) EA005314B1 (ru)
FR (1) FR2817750B1 (ru)
HK (1) HK1055906A1 (ru)
HU (1) HU229372B1 (ru)
IL (2) IL155428A0 (ru)
IS (1) IS2349B (ru)
MA (1) MA26969A1 (ru)
ME (2) MEP20408A (ru)
MX (1) MXPA03005221A (ru)
NO (1) NO332294B1 (ru)
NZ (1) NZ525661A (ru)
OA (1) OA12416A (ru)
PL (1) PL199846B1 (ru)
RS (1) RS50348B (ru)
SK (1) SK287115B6 (ru)
TW (1) TWI246926B (ru)
WO (1) WO2002047660A1 (ru)
ZA (1) ZA200303406B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641116A1 (en) * 2006-02-14 2007-08-23 Wyeth Aqueous pharmaceutical formulations of er.beta. selective ligands
GB0719180D0 (en) * 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
PE20091809A1 (es) 2008-04-17 2009-12-03 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
KR20120094557A (ko) * 2011-02-01 2012-08-27 동아제약주식회사 피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제
CN102908307A (zh) * 2011-08-03 2013-02-06 天津市嵩锐医药科技有限公司 供注射用盐酸决奈达隆药物组合物及其制备方法
AU2013288676A1 (en) * 2012-07-12 2015-02-05 Sanofi Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
WO2022083636A1 (zh) * 2020-10-20 2022-04-28 上海博志研新药物技术有限公司 盐酸决奈达隆药物组合物、其制备方法及应用
WO2023019993A1 (zh) * 2021-08-16 2023-02-23 上海博志研新药物技术有限公司 盐酸决奈达隆注射组合物、其制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP2004327321A (ja) * 2003-04-25 2004-11-18 Jst Mfg Co Ltd コネクタ

Also Published As

Publication number Publication date
NO20031958L (no) 2003-06-11
AU2002217229B2 (en) 2006-05-18
RS50348B (sr) 2009-11-10
ME00083B (me) 2010-10-10
CA2427375C (fr) 2011-02-01
SK7262003A3 (en) 2004-02-03
TWI246926B (en) 2006-01-11
FR2817750A1 (fr) 2002-06-14
WO2002047660A1 (fr) 2002-06-20
KR100849758B1 (ko) 2008-07-31
HU229372B1 (en) 2013-11-28
DE60125411D1 (de) 2007-02-01
AR031649A1 (es) 2003-09-24
PL362788A1 (en) 2004-11-02
ATE348599T1 (de) 2007-01-15
IS2349B (is) 2008-04-15
MEP20408A (en) 2010-06-10
IL155428A0 (en) 2003-11-23
CZ20031612A3 (cs) 2003-09-17
JP2004528277A (ja) 2004-09-16
IS6801A (is) 2003-04-30
NZ525661A (en) 2004-11-26
JP4399161B2 (ja) 2010-01-13
EP1343473A1 (fr) 2003-09-17
BG66187B1 (bg) 2011-12-30
NO332294B1 (no) 2012-08-20
AU1722902A (en) 2002-06-24
KR20030060985A (ko) 2003-07-16
BR0116060A (pt) 2004-03-02
CA2427375A1 (fr) 2002-06-20
BR0116060B1 (pt) 2013-12-31
HUP0500842A2 (hu) 2005-12-28
OA12416A (fr) 2006-04-18
US20040044070A1 (en) 2004-03-04
NO20031958D0 (no) 2003-04-29
BG107748A (bg) 2004-03-31
EP1343473B1 (fr) 2006-12-20
MA26969A1 (fr) 2004-12-20
YU46503A (sh) 2006-08-17
IL155428A (en) 2007-10-31
HK1055906A1 (en) 2004-01-30
SK287115B6 (sk) 2009-12-07
DE60125411T2 (de) 2007-10-11
EA005314B1 (ru) 2004-12-30
CN1479610A (zh) 2004-03-03
CZ297788B6 (cs) 2007-03-28
PL199846B1 (pl) 2008-11-28
ZA200303406B (en) 2004-05-03
CN1235566C (zh) 2006-01-11
US6939865B2 (en) 2005-09-06
FR2817750B1 (fr) 2003-02-21
MXPA03005221A (es) 2004-03-26

Similar Documents

Publication Publication Date Title
ES2244831T5 (es) Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
PT1299107E (pt) Solucoes estaveis muito concentradas de meloxicam
CO5700797A2 (es) Composicion de farmaco conjugado
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
DE60117248D1 (de) Parenterale lösung enthaltend amiodaron
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
EE200100066A (et) Naatriumkloriidi kasutamine kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsetekõrvaltoimete vähendamiseks
IS2214B (is) Meðhöndlun á mígreni með því að gefa inn alfa-lípósýru eða afleiður hennar
ES2197781B1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
CO4970704A1 (es) Solucion acuosa estable de em 12, y procedimiento de preparacion de dicha solucion
ATE350064T1 (de) Pharmazeutische zusammensetzungen von rapamycines
DK1181300T3 (da) 6-O-carbamatketolidderivater
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
SE9902742D0 (sv) New pharmaceutical formultion
DK1109806T3 (da) Komplekser af paroxetin med cyclodextriner eller cyclodextrinderivater
TH45760B (th) สารละลายพรูคาโลไพรด์สำหรับการให้ทางปาก

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU